Insmed Incorporated Income Statement 2025-2008 | INSM

Brief overview of revenue and earnings at Insmed Incorporated

The figures are compared over a five-year interval. Revenue reported by Insmed Incorporated was 164 million dollars at the beginning of the period and 606 million dollars at the end. Across the full period, sales moved by +268.8%; the average annual rate was 29.8%. This pace points to rapid expansion of the business.

Gross profit was $125 million at the start and $483 million at the end of the period (+288.2%). Direct costs grew more slowly than revenue and improved the economics of sales. Comparing the endpoints gives gross margins of 75.7% and 79.7%. The margin shift points to a more favorable sales-and-cost structure.

Over the period, EBITDA shifted from −$256 million to −$1.2 billion, a change of −382.7%. EBITDA underperformed the top-line trend. EBITDA margin was −155.8% at the start and −203.9% at the end. The margin contraction indicates weaker operating efficiency.

The final result was −294 million dollars initially and −1.3 billion dollars in the final year. Profitability deteriorated further over the five years.

The five-year change in capitalization reached +805.9%: from 3.5 billion dollars to 31.6 billion dollars. Investor expectations increased faster than reported performance.

Financial takeaway

Signs of deterioration dominate the five-year picture. Key strengths include better sales economics and a larger revenue base. The main areas of concern are declining net profitability, pressure on operating profitability and a low EBITDA margin. Further direction will depend on top-line growth, operating profitability, and net income.